In its recent Q1 2025 earnings call, executives from Palantir Technologies Inc. (NYSE:PLTR) expressed their support for DOGE. What Happened: Shyam Sankar, CTO and Executive Vice President of Palantir, voiced his backing for DOGE cuts, criticizing government overspending on unproductive projects, during the earnings call. “..this is the right thing for the country. Like we have way too much spend on things that do not work. The government has started to resemble a fine-marbled wagyu,” stated Sankar. Don't Miss: Shark Tank's Kevin O'Leary called Missing Ring his biggest mistake — Don't repeat history—invest in RYSE at just $1.90/share. The team behind $6B+ in licensing deals is now building the next billion-dollar IP empire — invest early at $2.25/share. Speaking specifically about the DOGE team overseen by Elon Musk, Sankar stated, “...to me, these guys are heroes. They are world-class technologists that could be choosing to do anything and instead, they are choosing to do this.” Palantir’s CEO, Alex Karp, echoed Sankar’s sentiments, highlighting the need for system pressure to eliminate fraud, waste, and abuse. Why It Matters: Palantir’s Q1 2025 earnings showed a revenue beat and an EPS in line with estimates, as reported. This strong performance may be linked to the company’s support for DOGE, a government efficiency initiative led by Elon Musk. In February 2025, Karp had expressed support for Musk’s efforts to streamline government spending, even referring to him as the “most important builder in the world.” He also anticipated a positive outcome from the DOGE initiative for Palantir in the same month. These developments indicate a strategic alignment between Palantir and DOGE, which could potentially influence the company’s future performance and growth. Despite a strong earnings report, Palantir stock plunged nearly 9% in Tuesday’s pre-market trading session. On a year-to-date basis, it surged 64.6%, as per data from Benzinga Pro. Read Next: Invest Where It Hurts — And Help Millions Heal: Invest in Cytonics and help disrupt a $390B Big Pharma stronghold. ‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. You can invest today for just $0.30/share with a $1000 minimum. Photo courtesy: slyellow / Shutterstock.com Send To MSN: Send to MSN Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Story Continues Get the latest stock analysis from Benzinga? This article Palantir Lauds Elon Musk's DOGE Cuts, Calls It 'The Right Thing For The Country:' Government Resembles A 'Marbled Wagyu' originally appeared on Benzinga.com View Comments
Palantir Lauds Elon Musk's DOGE Cuts, Calls It 'The Right Thing For The Country:' Government Resembles A 'Marbled Wagyu'
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...